|
Partial nephrectomy’s benefits unknown to some
ModernMedicine Radical nephrectomy has been shown to increase the risk of developing chronic kidney disease and associated cardiovascular complications when used to treat small renal tumors. Despite the risks, researchers from Memorial Sloan-Kettering Cancer Center … |
CELGENE CORPORATION : Study Evaluating REVLIMID® Combination … – 4-traders (press release)
|
CELGENE CORPORATION : Study Evaluating REVLIMID® Combination …
4-traders (press release) … today announced data from a study comparing melphalan, prednisone and REVLIMID (lenalidomide) (MPR) with high-dose chemotherapy and tandem autologous stem cell transplant (MEL200), as well as evaluating the effect of lenalidomide maintenance … |
Heart failure may provoke andropause symptoms – Healio
Heart failure may provoke andropause symptomsHealioAndropause symptoms affect nearly one-third of men with heart failure, despite their age. However, the development of heart failure provoked an acceleration of the natural aging process, thus leading t…
"Chronic Kidney Disease (Chronic Renal Failure) – Pipeline Review, H1 2013" Is … – SBWire (press release)
|
“Chronic Kidney Disease (Chronic Renal Failure) – Pipeline Review, H1 2013″ Is …
SBWire (press release) This report provides information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the … Remote people face heightened kidney riskNinemsn |
Study Evaluating REVLIMID® Combination Compared to Autologous Stem Cell … – Business Wire (press release)
|
Study Evaluating REVLIMID® Combination Compared to Autologous Stem Cell …
Business Wire (press release) … today announced data from a study comparing melphalan, prednisone and REVLIMID (lenalidomide) (MPR) with high-dose chemotherapy and tandem autologous stem cell transplant (MEL200), as well as evaluating the effect of lenalidomide maintenance … ASCO 2013 Multiple Myeloma Update – Day Two: Education SessionThe Myeloma Beacon |
Study Evaluating REVLIMID(R) Combination Compared to Autologous Stem Cell … – MarketWatch (press release)
|
Study Evaluating REVLIMID(R) Combination Compared to Autologous Stem Cell …
MarketWatch (press release) Study Evaluating REVLIMID(R) Combination Compared to Autologous Stem Cell Transplant with or without REVLIMID Maintenance in Newly-Diagnosed Multiple Myeloma Presented at ASCO. MEL200 demonstrated a longer median PFS and OS compared … ASCO 2013 Multiple Myeloma Update – Day Two: Education SessionThe Myeloma Beacon |
Israeli child's donated kidney saves Palestinian boy – Israel Today
|
Israeli child’s donated kidney saves Palestinian boy
Israel Today … the Times of Israel. Naom’s father told Israel’s News1 that for he and his wife, it made no difference that the recipient of their son’s kidney was a Palestinian Arab. PHOTO: 3-year-old Noam Naor, who tragically suffered brain death after falling … |
Blood donation opportunities with American Red Cross – fox6now.com
|
Blood donation opportunities with American Red Cross
fox6now.com MILWAUKEE (WITI) — The American Red Cross encourages eligible donors to give blood this summer, helping to ensure a sufficient supply for patients in need and allowing them to create their summer of stories. Below are just a few examples of patients … Red Cross explains blood donation processStanly News & Press Red Cross Blood Drive Becoming New RiverFest TraditionKAKE |
TG Therapeutics, Inc. Announces Presentation of Interim Results From Its Phase … – NASDAQ (press release)
|
TG Therapeutics, Inc. Announces Presentation of Interim Results From Its Phase …
NASDAQ (press release) NEW YORK, June 3, 2013 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. ( TGTX ) today announced preliminary results from a Phase 1 clinical study of single-agent ublituximab (TG-1101) in patients with rituximab relapsed and/or refractory Non-Hodgkin’s … |
TG Therapeutics , Inc . Announces Presentation of Interim Results From Its … – MarketWatch
|
TG Therapeutics , Inc . Announces Presentation of Interim Results From Its …
MarketWatch TG Therapeutics, Inc. (TGTX) today announced preliminary results from a Phase 1 clinical study of single-agent ublituximab (TG-1101) in patients with rituximab relapsed and/or refractory Non-Hodgkin’s Lymphoma (NHL), presented at the American Society … |